There is already some precedent for targeting the EAAT2 transporter as a therapy in ALS, as riluzole upregulates EAAT2 activity in spinal cord synaptosomes from rats [82]. The gene discussed is SLC1A2; the disease is amyotrophic lateral sclerosis.